ML351

ML351 is a potent, selective, and reversible small molecule inhibitor of 12/15-lipoxygenase (12/15-LOX), also known as Arachidonate 15-lipoxygenase (ALOX15). Developed through the NIH Molecular Libraries Program, it serves as a high-affinity chemical probe with significant selectivity over other lipoxygenase isoforms such as 5-LOX and 12-LOX. By blocking the enzymatic activity of 12/15-LOX, ML351 prevents the production of pro-inflammatory and pro-oxidant lipid mediators, thereby exerting neuroprotective effects. Preclinical research has demonstrated its ability to reduce neuroinflammation, mitigate hippocampal neuronal damage, and improve cognitive and behavioral outcomes in models of status epilepticus, ischemic stroke, and traumatic brain injury. It is currently utilized as a research tool to investigate the role of lipid signaling in neurodegeneration and oxidative stress-related pathologies.